121 related articles for article (PubMed ID: 21697041)
1. The expression levels of thrombospondin-1 in dermatofibroma and dermatofibrosarcoma protuberans.
Maekawa T; Jinnin M; Ohtsuki M; Ihn H
Eur J Dermatol; 2011; 21(4):534-8. PubMed ID: 21697041
[TBL] [Abstract][Full Text] [Related]
2. The expression levels and the differential expression of transforming growth factor-beta receptors in dermatofibroma and dermatofibrosarcoma protuberans.
Kubo M; Ihn H; Yamane K; Tamaki K
Br J Dermatol; 2006 May; 154(5):919-25. PubMed ID: 16634896
[TBL] [Abstract][Full Text] [Related]
3. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
Kahn HJ; Fekete E; From L
Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
[TBL] [Abstract][Full Text] [Related]
4. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma.
Mori T; Misago N; Yamamoto O; Toda S; Narisawa Y
J Dermatol; 2008 Jul; 35(7):419-25. PubMed ID: 18705829
[TBL] [Abstract][Full Text] [Related]
5. IGFBP7, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Li J; Yu Y; Yang Y; Wang L; Cao J; Liang X; Xiao X; Tu Y; Chen H
J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):382-5. PubMed ID: 21492256
[TBL] [Abstract][Full Text] [Related]
6. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.
Kim HJ; Lee JY; Kim SH; Seo YJ; Lee JH; Park JK; Kim MH; Cinn YW; Cho KH; Yoon TY
Br J Dermatol; 2007 Aug; 157(2):319-24. PubMed ID: 17596171
[TBL] [Abstract][Full Text] [Related]
7. Collagen triple helix repeat containing-1 in the differential diagnosis of dermatofibrosarcoma protuberans and dermatofibroma.
Wang L; Xiang YN; Zhang YH; Tu YT; Chen HX
Br J Dermatol; 2011 Jan; 164(1):135-40. PubMed ID: 20849518
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Li N; McNiff J; Hui P; Manfioletti G; Tallini G
Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
[TBL] [Abstract][Full Text] [Related]
9. [Differences of the molecular phenotypes and the histogenesis between dermatofibroma and dermatofibrosarcoma protuberans].
Xiong Y; Guo H; Zhang S; Zhang B; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):395-400. PubMed ID: 18677387
[TBL] [Abstract][Full Text] [Related]
10. A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma.
Labonte S; Hanna W; Bandarchi-Chamkhaleh B
J Cutan Pathol; 2007 Nov; 34(11):857-60. PubMed ID: 17944726
[TBL] [Abstract][Full Text] [Related]
11. The involvement of fibroblast growth factor receptor signaling pathways in dermatofibroma and dermatofibrosarcoma protuberans.
Ishigami T; Hida Y; Matsudate Y; Murao K; Kubo Y
J Med Invest; 2013; 60(1-2):106-13. PubMed ID: 23614918
[TBL] [Abstract][Full Text] [Related]
12. Expression of MMP-2, MMP-9 and MMP-11 in dermatofibroma and dermatofibrosarcoma protuberans.
Chen YT; Chen WT; Huang WT; Wu CC; Chai CY
Kaohsiung J Med Sci; 2012 Oct; 28(10):545-9. PubMed ID: 23089320
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of phosphorylated-STAT3 and phosphorylated-ERK protein in dermatofibrosarcoma protuberans.
Lin N; Urabe K; Moroi Y; Uchi H; Nakahara T; Dainichi T; Kokuba H; Tu Y; Furue M
Eur J Dermatol; 2006; 16(3):262-5. PubMed ID: 16709490
[TBL] [Abstract][Full Text] [Related]
14. Dermatofibroma and dermatofibrosarcoma protuberans: a comparative ultrastructural study.
Dominguez-Malagon H; Valdez-Carrillo Mdel C; Cano-Valdez AM
Ultrastruct Pathol; 2006; 30(4):283-91. PubMed ID: 16971353
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of platelet-derived growth factor and its receptors in fibrohistiocytic tumors.
Taniuchi K; Yamada Y; Nonomura A; Takehara K
J Cutan Pathol; 1997 Aug; 24(7):393-7. PubMed ID: 9274955
[TBL] [Abstract][Full Text] [Related]
16. Dermatofibrosarcoma protuberans: an analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression.
Sasaki M; Ishida T; Horiuchi H; MacHinami R
Pathol Int; 1999 Sep; 49(9):799-806. PubMed ID: 10504551
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75.
West KL; Cardona DM; Su Z; Puri PK
Am J Dermatopathol; 2014 May; 36(5):414-9. PubMed ID: 24162384
[TBL] [Abstract][Full Text] [Related]
18. Neurofibromatous changes in dermatofibrosarcoma protuberans: a potential pitfall in the diagnosis of a serious cutaneous soft tissue neoplasm.
Kovarik CL; Hsu MY; Cockerell CJ
J Cutan Pathol; 2004 Aug; 31(7):492-6. PubMed ID: 15239679
[TBL] [Abstract][Full Text] [Related]
19. CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Calikoglu E; Augsburger E; Chavaz P; Saurat JH; Kaya G
J Cutan Pathol; 2003 Mar; 30(3):185-9. PubMed ID: 12641778
[TBL] [Abstract][Full Text] [Related]
20. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.
Agarwal A; Gopinath A; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2017 Jul; 39(7):504-507. PubMed ID: 28609344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
